17 not yet recruiting. 17 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Not yet recruiting 17 |
| Phase 2 | 5 | Not yet recruiting 5 |
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA) Anakinra 100 Mg/0.67 Ml Inj Syringe, Saline Placebo/0.67 Ml Inj Syringe - Asthma (Diagnosis), Persistent Asthma | Phase 1 | Not yet recruiting | University of North Carolina, Chapel Hill | 60 | 2026-11-01 | 2026-07-15 |
| Subconjunctival Humira for Boston Keratoprosthesis Adalimumab Injection - Penetrating Keratoplasty, Multiple Graft Failure | Phase 1 | Not yet recruiting | Massachusetts Eye and Ear Infirmary | 8 | 2026-10-01 | 2026-08-31 |
| A Randomized, Double-Blind, Placebo-Controlled Phase Ib Study of Multiple Ascending Doses of EB070 Injection in Adults With Moderate-to-Severe Asthma EB070 - Asthma | Phase 1 | Not yet recruiting | Biotech Pharmaceutical Co., Ltd. | 20 | 2026-09-30 | 2026-10-21 |
| Efficacy and Safety of Yiqi Wenyang Sanhan Formula Combined With Acupoint Application in Patients With Combined Allergic Rhinitis and Asthma Syndrome During Remission and Yang-Deficiency Syndrome Yiqi Wenyang Sanhan Formula Combined with Acupoint Application, placebo of Yiqi Wenyang Sanhan Formula combined with acupoint application - Allergic Rhinitis With Asthma | Phase 1 | Not yet recruiting | Beijing Daxing District Hospital of Integrated Chinese and Western Medicine | 188 | 2026-09-01 | 2026-04-20 |
| Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis HXN6005, Placebo - Health Adult Subjects, Atopic Dermatitis (AD) | Phase 1 / Phase 2 | Not yet recruiting | Helixon Biotechnology (Suzhou) Co., Ltd | 67 | 2026-09-01 | 2026-08-24 |
| A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines TLL-018, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 1 / Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 36 | 2026-08-15 | 2026-08-24 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| A Clinical Study of HRS-8797 in Healthy Participants HRS-8797, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Chengdu Suncadia Medicine Co., Ltd. | 74 | 2026-07-01 | 2026-07-13 |
| Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2). Alpha-0261, Placebo - Chronic Spontaneous Urticaria (CSU), Healthy Volunteers | Phase 1 | Not yet recruiting | AlphaMol Science Ltd. (Shanghai) | 48 | 2026-07-01 | 2026-07-06 |
| A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants HXN5003, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Helixon Biotechnology (Suzhou) Co., Ltd | 28 | 2026-05-27 | 2026-04-24 |
| A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis IBI3033, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 16 | 2026-04-30 | 2026-04-24 |
| ADO-5030 in Bronchoconstriction Challenge, Phase 1b ADO-5030 - Asthma (Diagnosis) | Phase 1 | Not yet recruiting | Adovate | 36 | 2026-01-01 | 2026-01-22 |
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. DARATUMUMAB (DARZALEX®) - Toxic Epidermal Necrolysis, Immunotherapy | Phase 1 / Phase 2 | Not yet recruiting | Hospices Civils de Lyon | 9 | 2025-10-29 | 2025-08-07 |
| A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China new formulations of 611, existing formulations of 611 - Atopic Dermatitis | Phase 1 | Not yet recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 180 | 2025-07-01 | 2025-06-27 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria. HS-10561, Placebo - Chronic Spontaneous Urticaria | Phase 1 / Phase 2 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 150 | 2025-03-31 | 2025-03-07 |
| Efficacy and Safety of Oral Probiotics on Ocular Symptoms and Gut Microbiome of Children with Vernal Keratoconjunctivitis Probiotic, Placebo Drug - Probiotic, Ocular Surface Disease | Phase 1 | Not yet recruiting | Mohsen Pourazizi | 32 | 2025-02-01 | 2025-01-27 |
| Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma Lipopolysaccharides - Asthma; Eosinophilic, Asthma | Phase 1 | Not yet recruiting | National Jewish Health | 60 | 2024-04-01 | 2024-02-21 |
Dermatitis, Atopic (5) · Asthma (4) · Chronic Urticaria (3) · Disease (3) · Stevens-Johnson Syndrome (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Transitional Cell (1) · Conjunctivitis, Allergic (1) · Endometriosis (1) · Head and Neck Neoplasms (1) · Liver Cirrhosis (1) · Mesothelioma (1) · Multiple Myeloma (1) · Pancreatic cancer, adult (1)
Immune System Diseases (17) · Hypersensitivity, Immediate (14) · Skin Diseases (11) · Skin and Connective Tissue Diseases (11) · Dermatitis (7) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Respiratory Tract Diseases (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Lung Diseases (5) · Respiratory Hypersensitivity (5) · Skin Diseases, Eczematous (5) · Skin Diseases, Genetic (5)
Adalimumab (1) · Endotoxins (1) · Interleukin 1 Receptor Antagonist Protein (1) · Lipopolysaccharides (1) · Probiotics (1) · daratumumab (1)
Helixon Biotechnology (Suzhou) Co., Ltd (2) · Adovate (1) · AlphaMol Science Ltd. (Shanghai) (1) · Beijing Daxing District Hospital of Integrated Chinese and Western Medicine (1) · Biotech Pharmaceutical Co., Ltd. (1) · Chengdu Suncadia Medicine Co., Ltd. (1) · Hangzhou Highlightll Pharmaceutical Co., Ltd (1) · Hospices Civils de Lyon (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Martin Huellner (1) · Massachusetts Eye and Ear Infirmary (1) · Mohsen Pourazizi (1) · National Jewish Health (1) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (1)
China (7) · United States (4) · Australia (1) · France (1) · Switzerland (1)
Michelle Hernandez, MD (1) · Mohsen Pourazizi (1) · Thomas Dohlman, MD (1)
R34HL179910 (1)